Focus Partners Advisor Solutions LLC Buys New Position in Novo Nordisk A/S $NVO

Focus Partners Advisor Solutions LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,294 shares of the company's stock, valued at approximately $437,000.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $29,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at about $30,000. Finally, Disciplina Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. HSBC downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target on the stock. in a research note on Thursday, July 31st. UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. TD Cowen dropped their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, August 19th. Finally, Dbs Bank raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $81.00.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $55.15 on Friday. The company has a market cap of $246.23 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 1.95 and a beta of 0.66. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $138.22. The business has a 50 day moving average price of $59.46 and a 200-day moving average price of $67.62. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.